By Fineline Cube Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for marketing authorization of its programmed death-1 (PD-1) inhibitor Hetronifly (serplulimab) in combination with chemotherapy as a first-line treatment for unresectable locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC).
Regulatory Milestone & Expanding Indication Portfolio
| Parameter | Detail |
|---|---|
| Company | Shanghai Henlius Biotech, Inc. (HKG: 2696) |
| Drug Name | Hetronifly (serplulimab) |
| Regulatory Body | EMA CHMP (European Medicines Agency) |
| Current Status | Positive recommendation issued (final EC decision pending) |
| New Indication | First-line sqNSCLC + chemotherapy |
| Existing EU Approvals | ES-SCLC, nsqNSCLC, esophageal squamous cell carcinoma (ESCC) |
| Therapeutic Class | PD-1 immune checkpoint inhibitor |
Clinical Evidence from Phase III ASTRUM-004 Trial
Study Design & Population
- Trial Name: ASTRUM-004
- Design: Randomized, double-blind, international multicenter Phase III study
- Patient Population: Previously untreated patients with advanced sqNSCLC
- Arms: Serplulimab + chemotherapy vs. placebo + chemotherapy
- Geographic Scope: International enrollment across multiple countries
Key Efficacy Outcomes
- Overall Survival (OS): Statistically significant improvement vs. chemotherapy alone
- Progression-Free Survival (PFS): Demonstrated positive results in this key secondary endpoint
- Clinical Benefit: Significantly improved survival outcomes in untreated locally advanced/metastatic sqNSCLC
- Safety Profile: Manageable safety profile consistent with established PD-1 inhibitor experience
Strategic Market Position & Competitive Landscape
Expanding European Footprint
This recommendation marks Henlius’ fourth oncology indication in the European Union, establishing the company as a significant player in the competitive PD-1 inhibitor market. The sequential approvals demonstrate:
- Broad therapeutic utility across multiple solid tumor types
- Robust clinical development capabilities meeting stringent EU regulatory standards
- Strategic focus on high-burden cancers with substantial unmet medical needs
sqNSCLC Market Opportunity
Squamous NSCLC represents approximately 25-30% of all NSCLC cases in Europe, affecting an estimated 40,000-50,000 patients annually. The first-line treatment landscape has evolved to include immunotherapy combinations, but access to effective PD-1 inhibitors remains critical for optimal patient outcomes.
Hetronifly’s approval would provide European oncologists with an additional cost-effective PD-1 option backed by robust Phase III data, potentially influencing treatment guidelines and reimbursement decisions across EU member states.
Commercial Implications & Global Strategy
For Henlius Biotech, this regulatory milestone represents a significant achievement for a Chinese biopharmaceutical company in one of the world’s most stringent regulatory markets. The company’s success demonstrates:
- International clinical trial execution capabilities meeting global standards
- Regulatory expertise navigating complex EU approval processes
- Commercial potential to compete with established Western and Asian PD-1 inhibitors
The positive CHMP recommendation also validates Henlius’ strategy of developing broad-spectrum PD-1 applications across multiple tumor types, creating economies of scale in manufacturing, distribution, and market access negotiations.
With existing approvals in ES-SCLC, nsqNSCLC, and ESCC, plus this new sqNSCLC indication, Hetronifly becomes one of the most comprehensively indicated PD-1 inhibitors in the European market.
Future Development Pipeline
Henlius continues to expand Hetronifly’s clinical development program, with ongoing studies in additional tumor types and combination regimens. The company’s integrated approach combining internal development with strategic partnerships positions it well to maintain momentum in the highly competitive immuno-oncology space.
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, clinical development, and commercial expectations. Actual results may differ due to risks including final regulatory decisions, market competition, pricing negotiations, and evolving treatment guidelines.-Fineline Info & Tech